Longevity · Investigational
Vilon (Lys-Glu)
No lawful US pathway
01 · Overview
Vilon is a synthetic dipeptide consisting of lysine and glutamic acid (Lys-Glu) developed as part of the Khavinson bioregulator peptide research program. The proposal that it binds promoter-region DNA sequences and thereby modulates gene expression comes from molecular modelling of peptide-DNA complexes rather than from direct structural or in vivo demonstration (PMID 23484211).
In cultured human mesenchymal stem cells, the Lys-Glu peptide changed expression of several genes linked to cell aging, including IGF1 and NFkB, which is cell-culture evidence only (PMID 32399807). Vilon has been studied primarily within Russian research programs for immunomodulation and possible geroprotective effects, and detailed molecular characterization remains incomplete.
02 · Research summary & key findings
In female CBA mice given Vilon subcutaneously from mid-life, investigators reported increased physical activity and endurance, longer lifespan and fewer spontaneous tumors, with no unfavourable developmental effects; this evidence is animal-only (PMID 11140587, PMID 10944717). Published human evidence is limited to small, mostly Russian-language reports, including changes in immune and coagulation indices in elderly patients with type 1 diabetes (PMID 18306698) and a preliminary, uncontrolled experience report in elderly patients with colorectal cancer (PMID 16075684). Independent replication in large randomized trials reported in international peer-reviewed journals has not been published, and no Vilon product appears in the FDA drug approval database.
03 · Regulatory status
Vilon (Lys-Glu) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Vilon (Lys-Glu) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 3 FDA-approved compounds in Longevity
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Vilon (Lys-Glu) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
- Oral
References
- [1]A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice Dokl Biol Sci, 2000. PMID 10944717
- [2]Effect of vilon on biological age and lifespan in mice Bull Exp Biol Med, 2000. PMID 11140587
- [3][Application of peptide bioregulator in complex treatment of elderly cancer patients] Adv Gerontol, 2005. PMID 16075684
- [4][Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus] Adv Gerontol, 2007. PMID 18306698
- [5]Short cell-penetrating peptides: a model of interactions with gene promoter sites Bull Exp Biol Med, 2013. PMID 23484211
- [6]Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides Mol Biol Rep, 2020. PMID 32399807
Primary literature
- PubMed: "Vilon"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Vilon"
Registered interventional and observational studies, including status and phase.
- PubChem: "Vilon"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Longevity
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.